Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR - Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $35.00 target price on the biotechnology company's stock.

Several other analysts also recently issued reports on the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group increased their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $24.67.

Capricor Therapeutics Stock Performance

CAPR traded up $1.71 on Monday, reaching $20.57. 2,326,995 shares of the company's stock were exchanged, compared to its average volume of 1,142,896. The company's 50 day moving average is $9.38 and its 200-day moving average is $6.62. The company has a market cap of $657.81 million, a price-to-earnings ratio of -23.64 and a beta of 4.01. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Sell-side analysts forecast that Capricor Therapeutics will post -1.13 EPS for the current year.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 12.00% of the company's stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $133,000. Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at approximately $426,000. Renaissance Technologies LLC boosted its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. Main Street Financial Solutions LLC lifted its stake in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in Capricor Therapeutics during the second quarter worth $147,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.